Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4897MR)

This product GTTS-WQ4897MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4897MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1747MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ15080MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ6389MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ13410MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ7828MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ9494MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ5586MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ15275MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW